What we do Accretion Pharmaceuticals Ltd manufactures and markets tablets, capsules, oral liquids, external preparations, and oral powders, serving healthcare needs with ISO certified quality standards. |
Founded in 2,012 |
Market share Emerging Indian Contract Development and Manufacturing Organization (CDMO) with growing domestic presence and expanding global footprint. |
Problem solved Provides affordable, high-quality pharmaceutical products to meet diverse healthcare requirements, addressing accessibility and quality in domestic and export markets. |
Top clients or who we serve Serves pharmaceutical supply chains through direct sales, loan license, and contract manufacturing in B2B and B2C segments across India and abroad. |
Key management - |
Our journey and innovations Founded in 2012, started manufacturing in 2014, converted to limited company in 2023, successfully listed in 2025 with strong growth in revenue and profits. |
Where we operate Primarily operates in India with revenue from exports to international markets. |
Top products or what we offer Tablets, Capsules, Oral Liquids, External Preparations (ointments, creams, gels), Oral Powders (sachets, dry syrups). |
Top brands - |
Raw materials needed Pharmaceutical chemicals, active pharmaceutical ingredients, excipients for formulation of oral and topical products. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue mainly from recurring contract manufacturing and direct sales. |
Our industry position Growing player in pharmaceutical manufacturing with strong quality certifications and expanding market share. |
Financial highlights FY 2024-25 revenue Rs 57.38 crores and net profit Rs 6.79 crores, significant growth from previous year. |
Geographical revenue split India contributes 91.24% of revenue; outside India 8.76%. |
Order book - |
Whats driving growth Increasing demand, IPO funding, quality certifications, expanding product portfolio and export initiatives. |
Our future plans Expand capacities, enhance R&D, deepen export markets, and scale production. |
Our green promise Committed to environmental health and safety standards and sustainable operations. |
Our people and values 121 employees fostering a culture of dedication, compliance, and continuous development. |
Key challenges ahead Competition, regulatory compliance, scaling up production, and maintaining quality standards. |
Interesting facts IPO oversubscribed 7.67 times; rapid revenue growth within two years of listing. |
Risks and strategy Mitigates risks through strong corporate governance, compliance, and diversified customer base. |
